Skip to main content

Exelixis Reports 3Q Revenues Up

NEW YORK, Nov. 5, (GenomeWeb News) - South San Francisco-based Exelixis reported $12.4 million in revenues for the third quarter ending Sept. 30, up over revenues of $10.4 million for the same period in 2002.

 

The company reported a net loss of approximately $25 million, up over a net loss of $23 million for the third quarter in 2002.

 

The company had cash, cash equivalents, short-term investments, and restricted cash of approximately $219 million as of Sept. 30, compared to $222 million at December 31, 2002.

 

Research and development expenses for the quarter ended September 30, 2003 were $32 million compared to $29 million for the same quarter in 2002.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.